Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 05, 2021 16:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Present at the 7th Annual Truist Securities Life Sciences Summit
April 28, 2021 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 20, 2021 16:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines
April 19, 2021 07:30 ET
|
Translate Bio, Inc.
-- Multiple antigen constructs, including the construct used in MRT5500, induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies in multiple species -- -- Efficacy...
Translate Bio Announces Key Leadership Additions and Promotions
April 19, 2021 07:30 ET
|
Translate Bio, Inc.
-- Seasoned healthcare executive, Brendan Smith, appointed as Chief Financial Officer, bringingstrategic operations and financial leadership -- -- Appointments enhance capabilities across pulmonary...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 07, 2021 16:05 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 23, 2021 16:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Appoints Dr. Rand Sutherland as President
March 22, 2021 07:30 ET
|
Translate Bio, Inc.
-- 20 years of combined industry, medical and academic expertise in pulmonary and rare disease to support continued advancement of mRNA therapeutic pipeline -- LEXINGTON, Mass., March 22, 2021 ...
Translate Bio Announces Results from Second Interim Data Analysis from Ongoing Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis (CF)
March 17, 2021 16:05 ET
|
Translate Bio, Inc.
-- First inhaled mRNA therapeutic delivered in multiple doses to the lungs of CF patients is generally safe and well tolerated; no observed pattern of increases in ppFEV1 -- -- Data supports...
Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate
March 12, 2021 01:00 ET
|
Translate Bio, Inc.
-- Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels -- -- Expected to enroll 415 participants; interim results...